In this article, we will be taking a look at the 10 Best Biotech Stocks to Buy Under $10.

The head biotech analyst at Goldman Sachs, Salveen Richter, appeared on CNBC’s “Squawk Box” on July 25 to discuss various topics, including the current status of the biotech industry and what to expect from the earnings season.

She said that the biotech and healthcare industries have experienced several years of negative earnings revision cycles, and she wants to see these businesses now hitting the figures.

They have begun to show some steadiness, Richter continued, and Q2 is usually a stronger quarter. As a result, some biotech businesses in the sector could produce impressive financial outcomes.

According to the expert, launches and pipelines beyond statistics are two additional elements to consider in the sector.

She will continue to keep an eye on the several medicine launches that have occurred this year. Speaking of pipelines that go beyond statistics, she said that pain and Alzheimer’s disease have begun to receive attention this season.

With this in mind, let’s now take a look at the 10 best biotech stocks to buy under $10.  

Our Methodology 

For our methodology, we screened stocks with a share price below $10 and ranked them according to the number of hedge fund holders as of Q2 2025, based on data from the Insider Monkey database. Additionally, we included the share price as of the most recent closing (21 August) in the subheadings for clarity.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

Here is our list of the 10 best biotech stocks to buy under $10.  

10. ImmunityBio, Inc. (NASDAQ:IBRX)

Number of Hedge Fund Holders: 14 

Share Price: $2.26 

ImmunityBio, Inc. (NASDAQ:IBRX) is a commercial-stage biotechnology company developing next-generation immunotherapies and cell therapies to treat cancer and infectious diseases, and is among the best biotech stocks. Its lead product, ANKTIVA, is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer (NMIBC), designed to activate NK cells, T cells, and memory T cells for durable disease control.

In June 2025, the FDA granted Expanded Access authorization for ImmunityBio, Inc. (NASDAQ:IBRX)’s Cancer BioShield™ platform, anchored by ANKTIVA, to treat lymphopenia in patients with relapsed or refractory solid tumors. These patients typically have critically low lymphocyte counts after standard treatments like chemotherapy or radiation. Data presented at the 2025 ASCO Annual Meeting showed that restoring lymphocytes in this group significantly prolongs survival, highlighting the company’s potential to address one of the most dangerous side effects of cancer therapy.

The business is also broadening its pipeline. In August 2025, it launched a Phase 2 trial of ANKTIVA for Long COVID, exploring immune modulation for post-infectious chronic disease. Additionally, the corporation initiated ResQ201A, a randomized trial combining N-803 (an interleukin-15 superagonist) with a PD-1 inhibitor for second-line non-small cell lung cancer, with plans for global expansion.

For papillary-only NMIBC, the FDA previously issued a Refuse-to-File letter on a supplemental BLA, but ImmunityBio, Inc. (NASDAQ:IBRX) is resubmitting updated long-term trial data showing encouraging outcomes with ANKTIVA plus BCG. The company is also engaging with regulators to update clinical guidelines that could expand access for more bladder cancer patients.

9. AbCellera Biologics Inc. (NASDAQ:ABCL)

Number of Hedge Fund Holders: 17 

Share Price: $4.17 

AbCellera Biologics Inc. (NASDAQ:ABCL) is a Canadian biotechnology company using its antibody discovery platform to develop therapies for cancer, autoimmune, metabolic, and endocrine disorders. Long recognized for industry partnerships, the company is now advancing into clinical development with proprietary assets.

In August 2025, AbCellera Biologics Inc. (NASDAQ:ABCL) dosed the first participants in a Phase 1 trial of ABCL635, a non-hormonal antibody therapy targeting the neurokinin 3 receptor (NK3R) for vasomotor symptoms of menopause, such as hot flashes. Current treatments are largely hormone-based, making this candidate a potential breakthrough for millions of women seeking safer, long-acting alternatives. The trial will evaluate safety, pharmacokinetics, and pharmacodynamics in both healthy participants and postmenopausal women.

AbCellera Biologics Inc. (NASDAQ:ABCL) also received Health Canada approval to begin a Phase 1 trial of ABCL575, an antibody antagonist of OX40 ligand (OX40L) for atopic dermatitis and other inflammatory conditions. Preclinical data suggest it could inhibit T cell–mediated inflammation with extended dosing intervals, potentially improving efficacy and convenience for patients.